COMPARISON OF ROSUVASTATIN WITH ATORVASTATIN IN LOWERING LOW DENSITY LIPOPROTEIN CHOLESTEROL AMONG DYSLIPIDEMIC PATIENTS
Keywords:
Dyslipidemia, Rosuvastatin, Atorvastatin, Low Density Lipoprotein CholesterolAbstract
Objective: To compare the efficacy of Rosuvastatin with Atorvastatin therapy on low density lipoprotein cholesterol
(LDL-C) in patients with dyslipidemia after 12 weeks of treatment in a tertiary care hospital.
Material and Methods: This parallel-group, randomized, prospective, comparative, single center trial was conducted
in Department of Medicine, District Headquarter Teaching Hospital Dera Ismail Khan from June 2015 to January 2016.
This study included 200 patients with dyslipidemia, having LDL-C level of ? 130 mg/dl. Patients from both outpatient
department (OPD) and admitted were included in the study. Two groups of patients were made randomly. Patients in
Group A were treated with Rosuvastatin 10 mg/day and group B were treated with Atorvastatin 10 mg/day. Fasting
blood samples were collected from all designed patients in the start of study and after 12 weeks of treatment.
Results: Two hundred patients with dyslipidemia, having a serum low density lipoprotein levels ? 130 mg/dl were
included in the study. These patients were randomly divided into Group A and Group B, 100 in each group. There were
70 male and 30 female in group A while 75 male and 25 female in group B. Mean age in group A was 53±7.43 years
while in group B it was 52±8.12 years. The age ranged between 38 years and 70 years. Mean base LDL-C level was
160 mg/dl in the start of study. Low density lipoprotein levels were reduced by 29% with 10 mg/day of Rosuvastatin and
19% with 10 mg/day of Atorvastatin after twelve weeks treatment. The reduction in LDL-C for Rosuvastatin was more,
than for Atorvastatin. The independent sample-t test showed a statistically significant difference between the efficacy
of the two drugs, t (198) = 7.6, P<0.05, Cohen’s D= 5.14, effect size= 0.93.
Conclusion: Rosuvastatin 10 mg/day is more effective in reducing LDL-C levels as compared to Atorvastatin 10 mg/day.
Downloads
Published
How to Cite
Issue
Section
License
All articles published in the Journal of Medical Sciences (JMS) are licensed under the Creative Commons Attribution 4.0 International License (CC-BY 4.0). Under the CC BY 4.0 license, author(s) retain the ownership of the copyright publishing rights without restrictions for their content, and allow others to copy, use, print, share, modify, and distribute the content of the article even for commercial purposes as long as the original authors and the journal are properly cited. No permission is required from the author/s or the publishers for this purpose. Appropriate attribution can be provided by simply citing the original article. The corresponding author has the right to grant on behalf of all authors, a worldwide license to JMS and its licensees in all forms, formats, and media (whether known now or created in the future), The corresponding author must certify and warrant the authorship and proprietorship and should declare that he/she has not granted or assigned any of the article’s rights to any other person or body.
The corresponding author must compensate the journal for any costs, expenses, or damages that the JMS may incur as a result of any breach of these warranties including any intentional or unintentional errors, omissions, copyright issues, or plagiarism. The editorial office must be notified upon submission if an article contains materials like text, pictures, tables, or graphs from other copyrighted sources. The JMS reserves the right to remove any images, figures, tables, or other content, from any article, whether before or after publication, if concerns are raised about copyright, license, or permissions and the authors are unable to provide documentation confirming that appropriate permissions were obtained for publication of the content in question.
